This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent. Top assignee: Senju Pharmaceutical Co., Ltd.. Active years: 2000-2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kobe, JP (2000)
- Hyogo, JP (2015 - 2017)
Company Filing History:
Years Active: 2000-2017
Title: The Innovations of Shuichi Nishihata
Introduction
Shuichi Nishihata is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aqueous liquid compositions. With a total of 3 patents to his name, Nishihata's work has had a meaningful impact on the industry.
Latest Patents
One of his latest patents is an aqueous liquid bromfenac composition that possesses preservative efficacy. This composition includes bromfenac or a salt thereof, along with benzalkonium chloride. The unique aspect of this invention is that the concentration of benzalkonium chloride is higher than 0.0005% and lower than 0.005%. This formulation aims to enhance the stability and effectiveness of the medication.
Career Highlights
Shuichi Nishihata is currently employed at Senju Pharmaceutical Co., Ltd., where he continues to innovate and develop new pharmaceutical solutions. His expertise in creating effective compositions has positioned him as a valuable asset to the company.
Collaborations
Nishihata has worked alongside talented colleagues such as Wakiko Asayama and Suzuka Iemoto. Their collaborative efforts contribute to the advancement of pharmaceutical research and development.
Conclusion
Shuichi Nishihata's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving medical solutions. His work continues to influence the industry positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile